Join me at the Global Longevity Summit this October. Use code BEYONDTOMORROW for 10% off your ticket: https://informaconnect.com/global-longevity-summit

What if the key to living longer, healthier lives wasn’t a pill, diet, or workout—but rewriting our DNA? In this episode of Longevity Unpacked, we explore gene therapy with Liz Parrish, “patient zero” for longevity treatments and founder of BioViva, and Boyang Wang, investor and founder of Immortal Dragons, backing cutting-edge biotech companies.

Liz and Boyang take us inside the science, ethics, and future potential of gene therapy—from curing genetic diseases to extending healthspan. They share personal experiences, discuss regulatory challenges, and explain why billionaires may be leading the way for everyone else.

We also explore the economics: could gene therapy cost less than cancer treatment by 2040? Could it even become free? And what would it mean when therapies could boost muscle, brain function, telomeres, and resistance to age-related diseases?

Whether you’re curious about the science, excited for the future of medicine, or wondering when these treatments might be available, this episode gives a clear view of the opportunities—and risks—of gene therapy.

📌What You’ll Learn in This Episode:

What gene therapy actually is, explained in simple terms

The difference between monogenic and polygenic therapies

Liz Parrish’s personal journey as the first patient to undergo gene therapy for longevity

Why Boyang Wang decided to try gene therapy and invest in the space

The current state of regulation and approval worldwide

How delivery methods (vectors vs plasmids) change effectiveness

The role of billionaires as early test subjects for longevity treatments

Ethical questions around enhancement, embryos, and “playing God”

How gene therapy could reshape healthcare costs by 2040

Practical advice for patients, investors, and anyone interested in the future of longevity

⏱ Episode Timestamps

0:00 – Introduction & Liz’s journey as patient zero

2:08 – Why gene therapy could become essential for survival

5:00 – How gene therapy actually works (explained simply)

10:00 – The difference between monogenic and polygenic therapies

13:15 – Liz’s first treatments and why she took the risk

18:05 – Boyang’s personal motivation for trying gene therapy

23:34 – Vectors vs plasmids: why delivery matters

28:17 – Risks of moving too fast—or too slow—with regulation

33:29 – Billionaires as test subjects: ethical or essential?

36:11 – Will gene therapy cost less than cancer drugs by 2040?

42:03 – Will we see approved longevity therapies by 2030?

47:26 – Gene therapy and the ethics of embryonic editing

53:39 – Longevity, AI, and the future of human intelligence

57:20 – The biggest risks to the gene therapy industry today

1:03:38 – Special interests vs patient access: the real battle

1:07:47 – Advice for newcomers to the gene therapy space

1:10:13 – Boyang’s advice for investors in longevity

1:11:35 – Closing thoughts and next episode teaser

🎙 Hosted by Julian Issa 

📸 Instagram: @thebeyondtomorrowpodcast 

🌐 Website: www.beyondtomorrowpodcast.com 

📩 Email: bookings@beyondtomorrowpodcast.com 

🎧 Subscribe on Spotify, Apple, and YouTube for more stories from the edge of what’s possible.